Combination of TLR1/2 and TLR3 ligands enhances CD4+ T cell longevity and antibody responses by modulating type i IFN production

Bo Ryeong Lee, Soo Kyung Jeong, Byung Cheol Ahn, Byeong Jae Lee, Sung Jae Shin, Jung Sun Yum, Sang Jun Ha

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Despite the possibility of combining Toll-like receptor (TLR) ligands as adjuvants to improve vaccine efficacy, it remains unclear which combinations of TLR ligands are effective or what their underlying mechanisms may be. Here, we investigated the mechanism of action of L-pampo, a proprietary adjuvant composed of TLR1/2 and TLR3 ligands. L-pampo dramatically increased humoral immune responses against the tested target antigens, which was correlated with an increase in follicular helper T cells and the maintenance of antigen-specific CD4+ T cells. During the initial priming phase, in contrast to the induction of type I interferon (IFN) and pro-inflammatory cytokines stimulated by polyI:C, L-pampo showed a greatly diminished induction of type I IFN, but not of other cytokines, and remarkably attenuated IRF3 signaling, which appeared to be critical to L-pampo-mediated adjuvanticity. Collectively, our results demonstrate that the adjuvant L-pampo contributes to the promotion of antigen-specific antibodies and CD4+ T cell responses via a fine regulation of the TLR1/2 and TLR3 signaling pathways, which may be helpful in the design of improved vaccines.

Original languageEnglish
Article number32526
JournalScientific reports
Publication statusPublished - 2016 Sep 1

Bibliographical note

Funding Information:
This study was supported by a grant from the Korean Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare (HI14C2680, HI15C0493) and by the Basic Science Research Program (2012M3A9B4028264), the Bio & Medical Technology Development Program (2015R1A2A1A10056084), and the International Research & Development Program (2014K1A3A7A03075054) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning.

Publisher Copyright:
© 2016 The Author(s).

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Combination of TLR1/2 and TLR3 ligands enhances CD4+ T cell longevity and antibody responses by modulating type i IFN production'. Together they form a unique fingerprint.

Cite this